CAI Caris Life Sciences Inc.

$CAI Caris has a 9/10 growth outlook because it is expanding across several large, underpenetrated markets rather than relying on a single assay. The domestic addressable opportunity exceeds $100 billion annually, including approximately $10 billion for therapy selection, $20 billion for MRD and recurrence monitoring, and more than $70 billion for MCED. Therapy-selection penetration is only 35%, while blood-based monitoring remains early in adoption. Caris Detect launched commercially in July 2026 and targets 58 cancer types using ultra-deep WGS, WTS, and AI trained on more than one million real-world cases. Caris Assure volume grew 50% year over year in Q2 2026, and management is tripling laboratory capacity toward a $3.0 billion revenue run rate. The report models 15%–25% five-year revenue CAGR, with a base case of 18%, although commercial adoption, reimbursement, and operational scaling determine whether the upper end is achievable.

$CAI WES 23k + WTS 61k vs 500-gene panel. Q2 $263.7M +45%, 68% GM, net loss $0.6M near break-even. MI Cancer Seek Medicare $8,455. Does anyone track collection rate vs list price here?

$CAI look long-term easy new ATH in next Qs. DCA present we got for next run! i buy 50-100 next shares